Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RESP301 + isoniazid + rifampin + pyrazinamide + ethambutol
- Development stage
- Phase 2
- Lead developer
- 30 Technology
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation, Oral
01
Overview
This combination consists of RESP301, a nitric oxide (NO)-generating inhaled solution, together with four first-line oral anti-tuberculosis drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. RESP301 delivers inhaled NO directly to the respiratory tract, exerting direct antimicrobial activity (antiviral and antibacterial) and enhancing host defenses. Isoniazid inhibits mycolic acid synthesis in Mycobacterium tuberculosis. Rifampin blocks bacterial RNA polymerase. Pyrazinamide is bactericidal against replicating and dormant mycobacteria. Ethambutol impairs cell wall synthesis by inhibiting arabinosyl transferases. This combination is under clinical investigation for the treatment of pulmonary tuberculosis, with RESP301 adding a novel, inhaled mechanism to standard oral TB therapy[1][2][4].
- Other names
- RESP301 plus HRZERESP-301 plus HRZERESP 301 plus HRZEnitric oxide-generating solution + HRZE
02
Targets
embB (Arabinosyltransferase EmbB)Aspartate decarboxylaserpoB (DNA-directed RNA polymerase subunit beta)InhAPncA (Nicotinamidase)AftA (Arabinosyltransferase AftA)FASN (Fatty acid synthase)FAS-I (Mycobacterial fatty acid synthase I complex)
Beyond the preview
Go deeper on RESP301 + isoniazid + rifampin + pyrazinamide + ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RESP301 + isoniazid + rifampin + pyrazinamide + ethambutol.